|
Fibrin degradation product (FDPs), also known as fibrin split products, are components of the blood produced by clot degeneration. Clotting, also called coagulation, at the wound site produces a mass of fibrin threads called a net that remains in place until the cut is healed. As a cut heals, the clotting slows down. Eventually the clot is broken down and dissolved by plasmin. When the clot and fibrin net dissolve, fragments of protein are released into the body. These fragments are fibrin degradation products or FDPs. If your body is unable to dissolve a clot, you may have abnormal levels of FDPs. The most notable subtype of fibrin degradation products is D-dimer. The levels of these FDPs rise after any thrombotic event. Fibrin and fibrinogen degradation product (FDP) testing is commonly used to diagnose disseminated intravascular coagulation.〔(Fibrin/Fibrinogen Degradation Products )〕 ==As Tumor Marker== As Tumor Marker known as AMDL-ELISA DR-70 (FDP) and now as Onko-Sure has been approved by US FDA on July 1, 2008 for In vitro diagnostic only and serial testing for monitoring colorectal cancer with more effective by 50 percent than Carcinoembryonic antigen (CEA) when CEA values is low. Onko-Sure blood test can detect also tumors/cancers of: lung, breast, stomach, liver, colon, rectal, ovarian, esophageal, cervical, trophoblastic, thyroid, malignant lymphoma, and pancreatic.〔(【引用サイトリンク】title=510(k) summary: AMDL-ELISA DR-70® (FDP) )〕〔(【引用サイトリンク】title=Cancer Diagnostics )〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Fibrin degradation product」の詳細全文を読む スポンサード リンク
|